Table 1

Demographic and disease characteristics at baseline and at six month follow up in both groups. Unless otherwise indicated, values are the mean (SD)

Patients with SpA treated with etanercept (n=10)Patients with SpA treated conventionally (n=10)
Baseline6 Monthsp Value*Baseline6 Monthsp Value*
*Paired two tailed Student’s t test used to test differences between baseline and six month follow up values for both patient groups.
ESR, erythrocyte sedimentation rate (normal value 5–15 mm/1st h); CRP, C reactive protein (normal value <10 mg/l); VAS, visual analogue score; BASFI, Bath Ankylosing Spondylitis Functional Index (0–100); BASDAI, Bath Ankylosing Spondylitis Disease Activity Index (0–100).
Demographic variables
    Body weight (kg)70.1 (19.4)72.0 (19.1)0.2168.2 (11.0)69.1 (10.8)0.26
    Age (years)37.6 (8.3)30.2 (4.7)
    Body height (cm)168.3 (8.1)173.5 (8.6)
    Men97
    Disease duration (range)12 years (0.6–34)21 weeks (2–76)
Disease variables
    HLA-B27 positive (n)87
    ESR (mm/1st h)41.6 (23.3)10.9 (8.2)0.00228.5 (18.1)13.7 (12.0)0.07
    CRP (mg/l)48.2 (24.8)17.0 (20.3)0.02232.9 (16.5)14.6 (12.8)0.053
    Early morning stiffness (min)1202.50.00870 (50)33 (26)0.10
    VAS spinal pain during the day (0–100 mm)53.6 (25.6)16.3 (19.0)0.00254.3 (19.9)46.2 (32.6)0.52
    VAS spinal pain during the night (0–100 mm)58.9 (26.5)13.4 (20.7)0.00157.7 (26.4)36.8 (27.6)0.06
    VAS global disease activity (0–100 mm)69.6 (19.8)12.2 (19.1)<0.00147.4 (19.0)39.4 (29.8)0.54
    BASFI7.2 (1.8)4.0 (3.1)0.0025.2 (2.4)2.2 (2.1)0.10
    BASDAI6.7 (2.1)2.3 (2.4)<0.0016.8 (1.6)3.3 (2.6)0.13